JOINN Laboratories (China) Co., Ltd. (6127) announced its unaudited results for the third quarter of 2025. During the quarter, revenue stood at approximately RMB316.39 million, a 34.87% decrease year-on-year, attributed to intensified market competition and reduced gross profit margins. Net profit attributable to shareholders reached about RMB19.77 million, marking an 80.11% drop year-on-year, while net profit after non-recurring items fell 92.94% to RMB5.99 million.

From the start of 2025 through the end of the reporting period, the company recorded cumulative revenue of roughly RMB984.96 million, down 26.23% from the same period last year. Net profit attributable to shareholders rose to RMB80.71 million, whereas net profit after non-recurring items was RMB29.04 million. The change in fair value of biological assets contributed a net profit of around RMB140.17 million during the nine-month period, and fund management earnings added RMB45.77 million. Meanwhile, the laboratory services business reported a decline in gross profit due to price competition, affecting overall profitability.

New orders for the first three quarters reached about RMB1.64 billion, bringing total orders on hand to around RMB2.5 billion. The announcement highlights that execution and profitability may continue to be influenced by multiple factors. The financial statements were prepared under PRC Accounting Standards for Business Enterprises and remain unaudited.